Clinical trials: Complete Response
Colorectal Cancer
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
A novel evaluation model for identifying complete response following neoadjuvant immune checkpoint inhibitor therapy therapy in patients with dMMR colon cancer was developed to validated its efficacy in two independent cohorts…
- Trial name
- NCT06980350
- Testing
- PD-1 Inhibitors
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
- Trial name
- NCT00096460
- Testing
- Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy
- Where
- 30 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Infection, Candida
Early Diagnosis of Candidiasis in Premature Infants
This observational study evaluated the performance of new lab tests in detecting candida species fungal infections in extremely low birth weight (ELBW) infants quickly and accurately.
- Conditions
- Infection, Candida, Candidiasis, Infant, Newborn
- Trial name
- Candida (NCT00109525)
- Where
- 20 sites in United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- NICHD Neonatal Research Network
Bone Sarcoma, Osteosarcoma
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse.
- Trial name
- REGOMAIN (NCT04698785)
- Testing
- Treatment by regorafenib and best supportive care
- Where
- 16 sites in France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Carcinoma, Renal Cell
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Observational, retrospective, multicentre study in spanish patients with metastatic Renal Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with previous cytokine therapy is accepted) according to…
- Trial name
- ATILA (NCT03916458)
- Where
- 31 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Pfizer
Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
This study is a prospective, single center, phase II clinical study involving 108 patients with primary and late stage Diffuse Large B-cell Lymphoma complicated by large masses and extranodal involvement.
- Conditions
- Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy
- Trial name
- NCT05874778
- Testing
- 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy, Radiotherapy beyond standard R-CHOP Chemotherapy
- Volunteers
- 108 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Cancer, Organ Preservation
Treatment Strategy for Rectal Cancer Patients With Complete Clinical Response
This was a propensity-score matched observational analysis, comparing the oncological outcome of surgical resection vs watch and wait apporach for rectal cancer patients with a cCR.
- Trial name
- NCT03846726
- Testing
- standard TME surgery
- Where
- China
- Volunteers
- 513 people
- Sponsor
- Yuan-hong Gao
Neuroblastoma
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
This is a single-arm, multicenter clinical trial conducted in patients ≥ 12 months of age with high-risk neuroblastoma in first complete response.
- Trial name
- NCT06047535
- Testing
- Naxitamab
- Volunteers
- 62 people
- Sponsor
- SciClone Pharmaceuticals
Upper Respiratory Infections
Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting
The purpose of this study is to assess the accuracy and ease-of-use of a simplified FilmArray Respiratory Panel test (FilmArray RP EZ) when performed according to the manufacturer's instructions by personnel in laboratories…
- Trial name
- NCT02232711
- Where
- 4 sites in United States
- Volunteers
- 1,082 people
- Sponsor
- BioFire Diagnostics, LLC
Breast Neoplasms
Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing.
- Trial name
- SCAN-B (NCT02306096)
- Where
- 10 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Lund University
Cervical Cancer
Thunderbeat Technology vs Standard Bipolar Electro Surgery in Laparoscopic Radical Hysterectomy and Pelvic Lymphadenectomy for Cervical Cancer
This prospective randomized pilot study is aimed to verify if the operative time of a LRH with pelvic lymphadenectomy for early stage cervical cancer (FIGO stages IA2-IB1-IIA<2cm) and for advanced stage cervical cancer (FIGO…
- Trial name
- Thunder Cervix (NCT01717781)
- Testing
- Thunderbeat technology, Standard bipolar electrosurgery
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Catholic University of the Sacred Heart
Myelogenous Leukemia, Chronic, Chronic Phase
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission(CMR) while on…
- Trial name
- NCT01887561
- Testing
- dasatinib
- Where
- Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kanto CML Study Group
Leukemia, Myeloid
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
It is often impossible to find therapeutic target in intermediate-risk AML, so it is very important to select appropriate chemotherapy protocol to eliminate minimal residual disease (MRD) in these AML patients.
- Trial name
- NCT03417427
- Testing
- Decitabine and Ara-C, Ara-C
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xuejie Jiang
Complete Spinal Cord Injury, Surgery
Anesthetic Requirement and Stress Hormone Response During Surgery in Spinal Cord-injured Patients
Spinal cord injury (SCI) reduces anesthetic requirements and stress hormonal responses. Anesthetic requirements and stress hormone response are compared in SCI patients undergoing anesthesia with sevoflurane supplemented with…
- Trial name
- NCT01683916
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Chonnam National University Hospital
Rectal Cancer
Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
The goal of this observational study is to learn about the amide proton transfer-weighted imaging for rectal cancer response assessment after neoadjuvant therapy.
- Trial name
- NCT06719414
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Acute Myeloid Leukemia
Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)
Evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in the first CR (CR1).
- Trial name
- CBF(+)AML (NCT01146977)
- Testing
- HDAC chemotherapy, Autologous HCT
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Cooperative Study Group A for Hematology
Leukemia, Myeloid
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia
Primary study objective is the evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in the first CR (CR1) in terms of relapse incidence…
- Trial name
- NCT01050036
- Testing
- autologous hematopoietic cell transplantation
- Where
- 11 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Breast Neoplasms, Breast Cancer
Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers
A correlation between early changes in the tumor maximum standardized uptake value (SUVmax) on FDG-PET after one or two cycles of neoadjuvant chemotherapy (NAC) and the pathological response after 6 to 8 cycles has been…
- Trial name
- NCT02600442
- Testing
- non interventional study
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Invasive Aspergillosis
Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples
Diagnosing invasive pulmonary aspergillosis (IPA) remains a challenge in patients (pts) with hematological malignancies. The clinical significance of testing bronchoalveolar lavage (BAL) samples both with polymerase chain…
- Trial name
- NCT01430663
- Where
- 9 sites in Austria, Germany
- Volunteers
- 87 people
- Sponsor
- Heidelberg University
Acute Lymphoblastic Leukemia, B Cell ALL
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1
This investigator-initiated, prospective, single-arm, open-label, single-center phase II study aims to evaluate the long-term survival benefit and safety of a commercial CD19 CAR-T product in newly diagnosed Philadelphia…
- Trial name
- JUVENTAS-ALL05 (NCT06777264)
- Testing
- Biological: single dose of Inaticabtagene autoleucel
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Zhejiang University